Vertex Announces U.S. FDA Approval for TRIKAFTA? (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

View source version on?businesswire.com:?https://www.businesswire.com/news/home/20210609005466/en/
Vertex Pharmaceuticals Incorporated Investors: InvestorInfo@vrtx.com or 617-961-7163 Media: mediainfo@vrtx.com or U.S.: 617-341-6992 or International: +44 20 3204 5275 Source:?Vertex Pharmaceuticals Incorporated